Levetiracetam Solution
Product Images NDC 17856-0574

9 FDA label images from Atlantic Biologicals Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 17856-0574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Leve-structure (Leve Structure)

Leve-structure (Leve Structure)
Chemical structure of levetiracetam showing its cyclic amide ring, ethyl group, and amide side chain.*
FDA Label Image

Leve-figure1 (Leve Figure1)

Leve-figure1 (Leve Figure1)
A bar chart depicting the percentage of patients across three groups: Placebo (N=95) at 7.4%, Levetiracetam 1,000 mg/day (N=97) at 37.1%, and Levetiracetam 3,000 mg/day (N=101) at 39.6%. The y-axis shows the percentage of patients from 0% to 45%, and an asterisk marks the bars for Levetiracetam doses.*
FDA Label Image

Leve-figure2 (Leve Figure2)

Leve-figure2 (Leve Figure2)
Bar chart showing the percentage of patients associated with placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day groups. The vertical axis represents the percentage of patients, with values approximately 6.3% for placebo (N=111), 20.8% for Levetiracetam 1,000 mg/day (N=106), and 35.2% for Levetiracetam 2,000 mg/day (N=105).*
FDA Label Image

Leve-figure3 (Leve Figure3)

Leve-figure3 (Leve Figure3)
A bar graph comparing the percentage of patients in two groups: Placebo (N=104) with 14.4% and Levetiracetam 3,000 mg/day (N=180) with 39.4%. The vertical axis represents the percentage of patients from 0% to 45%.*
FDA Label Image

Leve-figure4 (Leve Figure4)

Leve-figure4 (Leve Figure4)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6%, and Levetiracetam (N=101) with 44.6%. The y-axis represents the percentage of patients, ranging from 0% to 45%. Asterisk marks above the Levetiracetam bar indicate statistical significance.*
FDA Label Image

Leve-figure5 (Leve Figure5)

Leve-figure5 (Leve Figure5)
Bar graph showing the percentage of patients in two groups: Placebo (N=51) at 19.6% and Levetiracetam (N=58) at 43.1%. The y-axis represents the percentage of patients, with values ranging from 0% to 45%. There is a statistical significance marker (*) above the Levetiracetam bar.*
FDA Label Image

Leve-figure6 (Leve Figure6)

Leve-figure6 (Leve Figure6)
Bar chart comparing the percentage of patients between a placebo group (N=84) and a Levetiracetam group (N=79). The placebo group shows 45.2% of patients, while the Levetiracetam group shows 72.2%. The chart includes a percentage scale on the y-axis from 0% to 100%.*
FDA Label Image

1 (17856 0574 01 Rev. 2 Case Label)

1 (17856 0574 01 Rev. 2 Case Label)
Label for Levetiracetam Oral Solution USP 100 mg/mL, delivering 500 mg per 5 mL, by Atlantic Biologicals Corp. The label indicates storage instructions (20° to 25°C), package quantity of 72 cups, and includes regulatory barcodes and product identifiers such as GTIN and serial number placeholders.*
FDA Label Image

3 (17856 0574 03 Rev.1 Case Label)

3 (17856 0574 03 Rev.1 Case Label)
Levetiracetam oral solution 100 mg/mL label, packaged by Unit Dose Solutions and distributed by Atlantic Biologicals Corp. The label shows the product NDC 17856-0574, dosage of 1000 mg/10 mL, quantity of 72 cups, and storage instructions to keep between 20° to 25°C (68° to 77°F). It includes a barcode, lot number, expiration date, and a reorder phone number 800-509-7592.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.